Pazopanib: Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Renal Cell Carcinoma and Soft Tissue Sarcoma

Pazopanib is an oral, multitargeted tyrosine kinase inhibitor with predominantly antiangiogenic activity. It inhibits several receptor tyrosine kinases involved in tumor vascularization and growth, particularly VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, and KIT. Through inhibition of these pathways, pazopanib reduces endothelial-cell proliferation, tumor angiogenesis, and tumor growth. DailyMed

In the United States, pazopanib is FDA approved for adults with advanced renal cell carcinoma (RCC) and for advanced soft tissue sarcoma (STS) after prior chemotherapy. Its efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors (GIST).

Key Facts

• Generic name: Pazopanib
• Drug class: Multitargeted tyrosine kinase inhibitor
• Major targets: VEGFR-1/2/3, PDGFR-α/β, KIT
• Route: Oral
• Initial US approval: 2009
• Tablet strength: 200 mg
• Standard dose: 800 mg once daily
• Administration: Without food, at least 1 hour before or 2 hours after a meal
• FDA-approved indications: Advanced RCC; previously treated advanced STS
• Boxed warning: Hepatotoxicity
• Major toxicities: Hepatotoxicity, hypertension, diarrhea, cardiac dysfunction, QT prolongation, hemorrhage, proteinuria, hypothyroidism, impaired wound healing
• Major interaction concerns: CYP3A4 inhibitors/inducers, P-gp/BCRP inhibitors, gastric acid-reducing agents, QT-prolonging drugs.

What Is Pazopanib?

Pazopanib is a small-molecule tyrosine kinase inhibitor designed primarily to suppress angiogenic signaling.

Its principal targets include:

• VEGFR-1
• VEGFR-2
• VEGFR-3
• PDGFR-α
• PDGFR-β
• KIT

These receptors contribute to:

• Tumor blood-vessel formation
• Endothelial-cell proliferation
• Stromal support
• Tumor-cell growth and survival

Pazopanib therefore acts mainly by disrupting the vascular support system that many tumors require for continued growth.

What Is the Mechanism of Action of Pazopanib?

1. Tumors Depend on Angiogenic Signaling

Many solid tumors produce:

VEGF

and other growth factors that stimulate endothelial cells and support formation of new blood vessels.

These signals act through receptors including:

• VEGFR-1
• VEGFR-2
• VEGFR-3
• PDGFR

2. VEGFR and PDGFR Activation Promotes Tumor Vascularization

Activated receptors stimulate intracellular pathways that promote:

• Endothelial-cell proliferation
• Migration
• Survival
• New blood-vessel formation

3. Pazopanib Blocks VEGFR and PDGFR Signaling

Pazopanib inhibits several receptor tyrosine kinases, particularly:

VEGFR-1/2/3 and PDGFR-α/β.

It also inhibits:

KIT.

4. Angiogenesis Falls

Reduced VEGFR and PDGFR signaling leads to:

• Less endothelial-cell proliferation
• Less tumor neovascularization
• Reduced vascular support

5. Tumor Growth Is Suppressed

The overall effect is:

• Reduced angiogenesis
• Reduced tumor-cell support
• Reduced proliferation
• Slower tumor progression

The mechanism can be summarized as:

Pazopanib → VEGFR/PDGFR/KIT inhibition → reduced angiogenic signaling → decreased tumor blood supply and growth.

What Is the Dose of Pazopanib?

The recommended dose is:

800 mg orally once daily

which equals:

Four 200 mg tablets once daily.

Treatment is continued until:

• Disease progression
• Unacceptable toxicity.

How Should Pazopanib Be Taken?

Pazopanib should be taken:

Without food.

Specifically:

• At least 1 hour before a meal, or
• At least 2 hours after a meal

The tablets should be:

Swallowed whole.

They should not be crushed because crushing increases systemic exposure and peak drug concentrations.

What If a Dose Is Missed?

If a dose is missed:

Do not take it if the next scheduled dose is less than 12 hours away.

Do not double the dose to compensate.

How Are Pazopanib Dose Reductions Made?

Dose reduction differs between RCC and STS.

Renal Cell Carcinoma

• Starting dose: 800 mg once daily
• First reduction: 400 mg once daily
• Second reduction: 200 mg once daily

If the patient cannot tolerate the second dose reduction, pazopanib should be permanently discontinued.

Soft Tissue Sarcoma

• Starting dose: 800 mg once daily
• First reduction: 600 mg once daily
• Second reduction: 400 mg once daily

If the patient cannot tolerate the second dose reduction, permanent discontinuation is recommended.

Dose Adjustment for Hepatic Impairment

Mild Hepatic Impairment

No routine starting-dose reduction is required.

Moderate Hepatic Impairment

Alternative treatment should be considered.

If pazopanib is used:

200 mg orally once daily.

Severe Hepatic Impairment

Pazopanib is:

Not recommended.

What Are the Important Drug Interactions With Pazopanib?

Pazopanib is metabolized primarily by:

CYP3A4

with smaller contributions from:

• CYP1A2
• CYP2C8.

Strong CYP3A4 Inhibitors

These can increase pazopanib exposure.

Examples include:

• Ketoconazole
• Itraconazole
• Clarithromycin
• Ritonavir

They should preferably be:

Avoided.

If unavoidable, reduce pazopanib to:

400 mg once daily.

Strong CYP3A4 Inducers

Strong inducers can reduce pazopanib concentrations.

Examples include:

• Rifampin
• Carbamazepine
• Phenytoin
• St. John’s wort

Alternative medications are preferred.

Chronic strong CYP3A4 induction should generally be avoided.

P-gp and BCRP Inhibitors

Strong inhibitors of:

• P-glycoprotein
• BCRP

may increase pazopanib concentrations and should generally be avoided.

Gastric Acid-Reducing Agents

Pazopanib absorption decreases when gastric pH rises.

For example, esomeprazole reduced pazopanib exposure by approximately:

40%.

Therefore avoid:

• Proton-pump inhibitors
• H2-receptor antagonists

when possible.

If acid suppression is unavoidable, short-acting antacids may be considered and should be separated from pazopanib by several hours.

Simvastatin

Concomitant simvastatin increases the risk of:

ALT elevations.

Liver monitoring should be intensified if this combination is used.

QT-Prolonging Drugs

Pazopanib can prolong QTc.

Avoid concomitant medications known to significantly prolong QT whenever possible.

Does Pazopanib Require Renal Dose Adjustment?

Pazopanib has very little renal elimination.

Less than:

4%

of the administered dose is eliminated renally.

Therefore routine starting-dose adjustment is generally not required for renal impairment.

Clinical data in severe renal dysfunction remain more limited than in patients with preserved renal function.

What Is the Pharmacokinetic Profile of Pazopanib?

Absorption

Peak concentrations are reached approximately:

2–4 hours

after administration.

Food Effect

Food substantially increases pazopanib exposure.

Both high-fat and low-fat meals increase:

• AUC by approximately 2-fold
• Cmax by approximately 2-fold

which is why pazopanib should be taken fasting.

Protein Binding

Pazopanib is:

>99% protein bound.

Half-Life

The mean elimination half-life is approximately:

31 hours.

Metabolism

Pazopanib is metabolized mainly by:

CYP3A4

with smaller contributions from:

• CYP1A2
• CYP2C8.

Elimination

Elimination is primarily:

Fecal.

Renal elimination accounts for:

<4% of the administered dose.

What Are the Clinical Uses of Pazopanib?

1. Advanced Renal Cell Carcinoma

Pazopanib is FDA approved for adults with:

Advanced RCC.

It became one of the major VEGFR-targeted agents used in metastatic clear-cell RCC and was historically an important first-line option.

2. Advanced Soft Tissue Sarcoma

Pazopanib is FDA approved for adults with:

Advanced soft tissue sarcoma after prior chemotherapy.

However, the label specifically notes that efficacy has not been established in:

• Adipocytic STS
• GIST.

Its use is therefore primarily relevant to non-adipocytic soft tissue sarcoma.

What Did the VEG105192 RCC Trial Show?

The pivotal randomized phase III study enrolled:

435 patients

with locally advanced or metastatic RCC.

Patients received:

• Pazopanib 800 mg once daily
• Placebo.

Progression-Free Survival

In the overall population:

• Pazopanib: 9.2 months
• Placebo: 4.2 months

Hazard ratio:

0.46

95% CI:

0.34–0.62

P < 0.0001.

Treatment-Naïve Patients

Median PFS:

• 11.1 months
• 2.8 months

HR:

0.40.

Cytokine-Pretreated Patients

Median PFS:

• 7.4 months
• 4.2 months

HR:

0.54.

Objective Response Rate

ORR was:

• 30% with pazopanib
• 3% with placebo.

Final Overall Survival in RCC

Final overall survival analysis was complicated by crossover from placebo to pazopanib.

The phase III trial nevertheless confirmed durable activity and established pazopanib as an effective VEGFR-targeted therapy in advanced RCC.

What Did the COMPARZ Trial Show?

COMPARZ directly compared:

Pazopanib 800 mg once daily

with:

Sunitinib 50 mg once daily on a 4-weeks-on/2-weeks-off schedule

in:

1,110 patients

with previously untreated metastatic clear-cell RCC.

The study demonstrated that pazopanib was:

Noninferior to sunitinib for progression-free survival.

Hazard ratio for progression or death:

1.05

95% CI:

0.90–1.22.

Overall survival was also similar:

HR 0.91.

Quality-of-life measures generally favored pazopanib, while toxicity profiles differed between the drugs.

What Did the PISCES Trial Show?

The randomized crossover PISCES study examined patient preference between:

• Pazopanib
• Sunitinib

among patients with metastatic RCC.

Among evaluable patients:

• 70% preferred pazopanib
• 22% preferred sunitinib
• 8% had no preference

P < 0.001.

The main reasons for preferring pazopanib were:

• Less fatigue
• Better overall quality of life.

What Did the PALETTE Trial Show?

The pivotal phase III PALETTE trial evaluated pazopanib in:

Metastatic non-adipocytic soft tissue sarcoma after previous chemotherapy.

A total of:

369 patients

were randomized:

• Pazopanib: 246
• Placebo: 123.

Progression-Free Survival

Median PFS was:

• 4.6 months with pazopanib
• 1.6 months with placebo

Hazard ratio:

0.31

95% CI:

0.24–0.40

P < 0.0001.

Overall Survival in PALETTE

Median OS was:

• 12.5 months
• 10.7 months

Hazard ratio:

0.86

P = 0.25.

The difference was not statistically significant.

Is Pazopanib FDA Approved?

Yes.

FDA-approved indications are:

Advanced RCC

For adults with advanced renal cell carcinoma.

Advanced STS

For adults with advanced soft tissue sarcoma after prior chemotherapy.

However, efficacy has not been demonstrated for:

• Adipocytic STS
• GIST.

What Is the Current Clinical Role of Pazopanib in 2026?

Renal Cell Carcinoma

Pazopanib remains FDA approved and biologically active in advanced RCC, but its role has narrowed substantially because contemporary RCC treatment is dominated by:

• Immune-checkpoint inhibitor combinations
• ICI + VEGFR-TKI combinations
• Newer targeted agents

Pazopanib therefore tends to be considered more selectively when an established VEGFR TKI is clinically appropriate.

Its historical relevance remains important because COMPARZ demonstrated efficacy comparable with sunitinib, while PISCES showed strong patient preference for pazopanib based largely on quality-of-life considerations.

Soft Tissue Sarcoma

Pazopanib remains an important oral targeted option for:

Previously treated advanced non-adipocytic soft tissue sarcoma.

This remains one of its most clinically relevant roles because PALETTE demonstrated a substantial PFS benefit after prior chemotherapy.

Its activity has been particularly incorporated into treatment strategies for selected sarcoma subtypes such as:

• Leiomyosarcoma
• Synovial sarcoma
• Other eligible non-adipocytic STS

while adipocytic sarcoma and GIST fall outside its established FDA evidence base.

Read more: ASTAR IMCB study led by Valerie Yang identified AZD5153 and Pazopanib drug combination for soft tissue sarcoma treatment — OncoDaily coverage of a precision-oncology study using pazopanib in STS.

Watch more: OncoDaily discussion on immunotherapy in Soft Tissue – 5 min Sarcoma Talk  with Sandra D’Angelo

What Are the Major Side Effects of Pazopanib?

Common adverse effects include:

• Diarrhea
• Hypertension
• Nausea
• Fatigue
• Reduced appetite
• Vomiting
• Weight loss
• Hair-color changes
• Elevated liver enzymes

Important serious toxicities include:

• Hepatotoxicity
• QT prolongation
• Cardiac dysfunction
• Hemorrhage
• Arterial thromboembolic events
• Venous thromboembolism
• Thrombotic microangiopathy
• GI perforation or fistula
• ILD/pneumonitis
• PRES
• Proteinuria
• Hypothyroidism
• Impaired wound healing.

Hepatotoxicity

Pazopanib carries an FDA:

Boxed warning for hepatotoxicity.

Severe and fatal liver injury has occurred.

Monitor:

• ALT
• AST
• Bilirubin

at:

• Baseline
• Regularly during treatment
• As clinically indicated

Most transaminase elevations occur relatively early; approximately 92% of any-grade transaminase elevations occurred within the first 18 weeks in clinical development.

Depending on severity, management may require:

• Interruption
• Dose reduction
• Permanent discontinuation

with intensified weekly liver-function monitoring in selected cases.

Hypertension

Hypertension occurs in approximately:

40%

of patients treated with pazopanib.

Grade 3 hypertension occurs in approximately:

4%–7%.

A substantial proportion develops early:

• About 40% of cases by Day 9
• About 90% within the first 18 weeks.

Do not start pazopanib in patients with uncontrolled hypertension.

Blood pressure should be optimized before treatment and monitored regularly thereafter.

Cardiac Dysfunction

Pazopanib can cause:

• Decreased LVEF
• Congestive heart failure

In COMPARZ, myocardial dysfunction occurred in approximately:

13%

of patients with baseline and follow-up LVEF measurements.

Congestive heart failure occurred in approximately:

0.5%.

Patients at higher risk include those with:

• Previous anthracycline exposure
• Cardiovascular disease
• Uncontrolled hypertension

Consider baseline and periodic LVEF assessment in at-risk patients.

QT Prolongation

Pazopanib can prolong the:

QT/QTc interval.

QT prolongation ≥500 msec occurred in approximately:

2%

of monitored RCC-trial patients.

Torsades de pointes occurred in:

<1% of pazopanib-treated patients across monotherapy trials.

In patients at increased risk:

Monitor:

• ECG
• Potassium
• Magnesium
• Calcium

and correct electrolyte abnormalities.

Hemorrhage

Pazopanib can increase bleeding risk.

In the pivotal RCC trial:

13%

of patients receiving pazopanib experienced at least one hemorrhagic event.

Potential events include:

• Hematuria
• Epistaxis
• Hemoptysis
• Gastrointestinal bleeding
• Genitourinary hemorrhage

Serious bleeding may require:

• Treatment interruption
• Dose reduction
• Permanent discontinuation.

Venous Thromboembolism

VTE, including pulmonary embolism, has been reported.

In the pivotal STS trial:

5%

of pazopanib-treated patients experienced VTE.

Fatal pulmonary embolism occurred in approximately:

1%.

Monitor for:

• Leg swelling
• Chest pain
• Dyspnea
• Hypoxia

Proteinuria

Proteinuria occurred in:

9%

of pazopanib-treated patients in the randomized RCC trial.

Monitoring should include:

• Baseline urinalysis
• Periodic urinalysis
• 24-hour urine protein measurement when clinically indicated

Nephrotic syndrome requires:

Permanent discontinuation.

Hypothyroidism

Hypothyroidism occurred in approximately:

• 7% in the pivotal RCC trial
• 5% in the pivotal STS trial.

Monitor thyroid function:

• At baseline
• During treatment
• As clinically indicated.

Gastrointestinal Perforation and Fistula

GI perforation or fistula occurred in approximately:

• 0.9% in RCC trials
• 1% in STS trials.

GI perforation requires:

Permanent discontinuation.

Interstitial Lung Disease/Pneumonitis

ILD/pneumonitis is rare but potentially fatal.

It occurred in approximately:

0.1% of pazopanib-treated patients.

Pazopanib should be permanently discontinued if ILD/pneumonitis develops.

Impaired Wound Healing

Because pazopanib inhibits VEGF signaling, it may impair wound healing.

Withhold pazopanib:

At least 1 week before elective surgery.

After major surgery:

Do not resume for at least:

2 weeks

and until adequate wound healing has occurred.

What Monitoring Is Required?

Monitoring during pazopanib therapy should include:

• ALT
• AST
• Bilirubin
• Blood pressure
• ECG in patients at QT risk
• Potassium
• Magnesium
• Calcium
• Clinical signs of heart failure
• LVEF in at-risk patients
• Signs of bleeding
• Signs of arterial or venous thromboembolism
• Urinalysis / urine protein
• Thyroid function tests
• Respiratory symptoms
• GI symptoms suggesting perforation or fistula
• Wound healing around surgery
• Concomitant CYP3A4, P-gp, BCRP, acid-suppressive, and QT-prolonging medications.